Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CEO Sells 1,532 Shares of Stock
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) traded up 4.52% on Wednesday, hitting $68.73. The company had a trading volume of 1,847,081 shares. The stock’s market capitalization is $1.73 billion. The firm’s 50 day moving average price is $94.11 and its 200-day moving average price is $111.08. Intercept Pharmaceuticals, Inc. has a 52 week low of $54.98 and a 52 week high of $156.65.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. During the same quarter last year, the company earned ($3.14) EPS. The firm’s revenue for the quarter was up 459.6% on a year-over-year basis. Analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.99) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by Marea Informative and is owned by of Marea Informative. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at http://www.mareainformativa.com/insider-selling-intercept-pharmaceuticals-inc-icpt-ceo-sells-1532-shares-of-stock/116206/.
A number of hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in Intercept Pharmaceuticals by 0.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its stake in Intercept Pharmaceuticals by 1.1% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 43 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in Intercept Pharmaceuticals by 1.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 62 shares during the last quarter. WFG Advisors LP boosted its stake in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intercept Pharmaceuticals by 14.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 132 shares during the last quarter. 82.19% of the stock is owned by institutional investors.
A number of equities research analysts have weighed in on ICPT shares. Royal Bank Of Canada started coverage on Intercept Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 target price for the company. Laidlaw reduced their price objective on Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating for the company in a research note on Friday, September 22nd. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Finally, Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and an average target price of $162.88.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.